In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Blackstone Funds New CAR-T Company with $250M Series A; Company Named AvenCell Therapeutics

Executive Summary

Funds managed by Blackstone Life Sciences have committed $250M towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company created by Intellia Therapeutics and Cellex Cell Professionals GmbH, the parent company of cell therapy company GEMoaB GmbH. The new firm will combine GEMoaB’s world-leading clinical-stage universal CAR-T platforms with Intellia’s differentiated allogeneic cell platform and CRISPR cell engineering to discover allogeneic universal CAR T-cell therapies for immuno-oncology and autoimmune diseases.

Update 02/24/2022

In its 10-K filing, Intellia revealed that the new company has been named AvenCell. Blackstone has approximately 33% ownership of the company (equal to Intellia and Cellex). See related deal profile for further details on licensing and development collaboration information between Intellia and AvenCell.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies